Oxford Nanopore and PathoQuest intend the ISA test to be the first in a line of sequencing-based quality control test solutions targeting the biopharma genetic characterisation and safety markets.

Gordon Sanghera, Oxford Nanopore Technologies Chief Executive ... They are also used for detecting microorganisms in food, pharmaceutical and cosmetic products. Learn more: www.biomerieux.com ...

Oxford Nanopore has developed a new generation of DNA/RNA sequencing technology. It is the only sequencing technology that offers real-time analysis in fully scalable formats from pocket to population ...

In biopharma, we have customers from across ... Before I wrap up, I wanted to remind you that the opportunity that Oxford Nanopore has ahead is not restricted to the current sequencing market.

Second-half revenue grew 34% from a year earlier, as Oxford Nanopore stepped up its expansion into customer endmarkets outside of research, toward applied industrial, biopharma, and clinical ...

Oxford Nanopore Technologies has signed a partnership ... the U.K. company worked with PathoQuest to develop quality control tests for the biopharma industry to check the safety of biologics ...

Oxford Nanopore Technologies aims to apply its super ... with PathoQuest to develop a quality control test for the biopharma industry to check the safety of biologic therapeutics including cell ...

Gene-sequencing company Oxford Nanopore Technologies Plc’s shares ... war eclipsed the firm’s plans to forge ties with the pharmaceutical industry. The shares fell about 15% in London, the ...

Growth was driven by expansion into end-markets outside of Research, such as Applied Industrial, BioPharma and Clinical, Oxford Nanopore said. The figure includes an around GBP16 million combined ...

(Alliance News) - Oxford Nanopore Technologies PLC on Tuesday ... particularly in Applied Industrial, up 42%, BioPharma, up 18%, and Clinical, up 12%, segments. Despite the top-line growth ...

Our investment from Novo Holdings reinforces and validates Oxford Nanopore's strategy and future growth plans across each of its end markets, which include research, biopharma, clinical and ...